The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutics Development Initiative, 2010Development of an Adult Adherent Allogeneic Stem Cell Product for Treatment of Parkinson's Disease
Objective/Rationale:
Previously published data illustrates that MultiStem®, an adult stem cell product approved by the FDA for Phase I studies in humans, works through multiple mechanisms of benefit... -
Rapid Response Innovation Awards, 2010Determine the Structure of Roco Family Proteins
Objective/Rationale:
Our aim is the biochemical and structural characterization of the Roco family of proteins. Structures of different Roco constructs will give important insights in the molecular... -
Pharmacodynamic Biomarkers of LRRK2 Activity, 2010Exploiting Ser910/935 Phosphorylation and 14-3-3 Binding to Develop Biomarkers for LRRK2 Activity
Objective/Rationale:
There is great excitement that drugs that target an enzyme termed LRRK2 may have utility for the treatment of Parkinson’s disease. Many companies are attempting to develop LRRK2... -
Pharmacodynamic Biomarkers of LRRK2 Activity, 2010Macrophage Precursors as Biomarker for LRRK2-associated Parkinson disease
Objective/Rationale:
LRRK2 mutations significantly contribute to the development of Parkinson Disease, a multisystem disorder. Neuronal loss is a prerequisite to develop the disease and a crosstalk... -
Pharmacodynamic Biomarkers of LRRK2 Activity, 2010Increased Dopamine Turnover as a Manifestation of LRRK2 Mutation
Objective/Rationale:
Mutations in LRRK2 represent the single most important cause of dominantly inherited Parkinson’s. We have previously shown that people with LRRK2 mutations have abnormal dopamine... -
Novel Hypotheses in Parkinson's Disease, 2010Characterization of PP2A as a Novel Therapeutic Target and a Biomarker of PD
Objective/Rationale:
Protein phosphatase 2A (PP2A) is a key enzyme that dephosphorylates proteins. PP2A deficits may be critical causes of Parkinson’s disease (PD) - abnormalities in PP2A levels and...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.